Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Next Previous
Trial Profile

A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis (X-PLORE)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guselkumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms X-PLORE
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 06 Apr 2023 Results of pooled analysis from Phase 2/3 studies (X-PLORE, VOYAGE 1, VOYAGE 2, NAVIGATE, ORION, ECLIPSE, Japan registration) assessing guselkumab safety in patients with psoriasispublished in the British Journal of Dermatology
    • 17 Jan 2018 Results (n=1459) of pooled data from (VOYAGE 1, X-PLORE and VOYAGE 2) assessing efficacy and safety of guselkumab for the treatment of moderate to severe psoriasis, were published in the Journal of Clinical Pharmacology.
    • 25 Nov 2016 According to a Janssen media release, the company has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking approval of guselkumab for the treatment of adults living with moderate to severe plaque psoriasis. Data from three phase III studies (VOYAGE 1, VOYAGE 2, NAVIGATE) and a phase II study (X-PLORE8) supported the application.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top